Mizuho Securities analyst Difei Yang maintained a Hold rating on Marinus (MRNS) today and set a price target of $5. The company’s shares closed on Friday at $3.84.
Yang commented:
“We continue to believe that postpartum depression (PPD) is the main value driver for MRNS and upcoming data in 2Q19 will likely be a key catalyst.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 17.9% and a 51.3% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Marinus with a $18.13 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.54 and a one-year low of $2.36. Currently, Marinus has an average volume of 839.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.
